Moderna’s Covid Vaccine Candidate



Day 113: Stay Safe Minnesota

The Moderna Therapeutics‘s vaccine shown promising results in an early trial of data to be published in a peer-reviewed journal.

In a previous post, it was noted that the Moderna biotechnogy company has developed messenger RNA (mRNA) based COVID-19 vaccine in collaboration with the National Institute of Allergy and Infectious Diseases. Now there are reports that Moderna’s experimental COVID-19 vaccine has shown promising results in an early trial of data to be published in a peer-reviewed journal.

“A preliminary report published yesterday in the New England Journal of Medicine on an ongoing phase 1 clinical trial of the mRNA-1273 COVID-19 vaccine developed by Moderna and study sponsor the US National Institute of Allergy and Infectious Diseases (NIAID) showed that it generated an immune response in healthy adults and was generally well tolerated.” – CIDRAP

The Forbes Business write Siladitya Ray writes: “Moderna’s Covid Vaccine Candidate Elicits ‘Robust’ Antibody Response In All Participants In First Trial.” The following key findings of the trial, lifted directly from the Forbes post include:

  • The antibody levels observed in all 45 participants were on the upper half of what has been seen in patients who’ve recovered from the disease.
  • The antibody response does not prove that the vaccine will be effective but it fulfills an important first goal of the test.
  • The 15 participants who received the highest dose of the vaccine displayed antibody levels that were four times higher than the recovered patients.
  • While the vaccines did not show serious toxicity, more than half of the participants experienced mild side effects including moderate fatigue, chills, headaches, and muscle pain.
  • Three of the patients who received the highest dose of the vaccines experienced severe side effects, the report notes, without elaborating further.
  • Moderna has stated that the high 250 microgram dosage will not carry forward to its expanded trial, which will enroll 30,000 participants.
  • Evaluation of the durability of immune responses is ongoing, Moderna said in a press release, adding that participants will be followed for one year after the second vaccination.
  • Moderna’s stock is up 9.8% in after-hours trading following the publication of the results.

It’s reported that “the vaccine appeared safe and generally well-tolerated by participants, although more than half of participants experienced some side effects, including fatigue, chills, headache, muscle aches and pain at the injection site”.

According to the New York Times, Moderna has started a Phase 2 trial, and plans to start a large Phase 3 trial with 30,000 participants on July 27.

Coronavirus Pandemic Watch

According to the MDH latest tally (as of July 16, 11 a.m.) the confirmed COVID-19 cases in Minnesota are 44,347 (out of 805,212 tested) with 1,526 deaths. According to Johns Hopkins database (as of July 16, 5:35 p.m.) there are 3,499,398 confirmed covid19 infection with 137,419 deaths. Globally the covid19 virus has infected 13,578,608 with 584,782 deaths.